uploads/2018/08/dna-163466_1280.jpg

Bluebird Bio Misses Analysts’ Estimates in Q2 2018

By

Updated

A look at Bluebird Bio’s Q2 2018 earnings

Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates. It reported EPS of -$2.91 on revenue of $7.8 million during Q2 2018, compared with -$2.35 on revenue of $9.6 million. The chart below compares the company’s revenue and EPS since Q1 2017.

Article continues below advertisement

Q2 2018 revenue

In the second quarter, Bluebird Bio’s revenue fell 53% YoY (year-over-year) to $7.85 million from $16.72 million. Its collaboration revenue rose ~21% YoY to $7.4 million from $6.1 million, while its license and royalty revenue fell ~96% YoY to $0.4 million from $10.6 million. Its net loss expanded YoY to ~$146.0 million from ~$67.8 million, or to $2.91 from $1.73 per share.

The company raised ~$600.6 million through a public offering of common stock in July. The VanEck Vectors Biotech ETF (BBH) invests 1.2% of its holdings in Bluebird Bio, 1.3% in Ionis Pharmaceuticals (IONS), 2.6% in Seattle Genetics (SGEN), and 4.5% in BioMarin Pharmaceutical (BMRN).

Advertisement

More From Market Realist